医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Thermo Fisher Scientific and West China Hospital Partner on Joint Research Platform for Precision Medicine

2016年06月13日 PM09:00
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a partnership with West China Hospital of Sichuan University, one of the largest single-site hospitals in the world, to develop a joint platform to research precision medicine. The partners shared the news during the seventh round of the China-U.S. High-Level Consultation on People-to-People Exchange (CPE) held in Beijing on June 6-7.

“Our company mission – to enable our customers to make the world healthier, cleaner and safer – is perfectly aligned with the priorities in China’s 5-year plan,” said Marc N. Casper, president and chief executive officer of Thermo Fisher. “We share a commitment to advancing precision medicine, and we’re excited about strengthening our collaboration with West China Hospital to provide technologies and expertise that will ultimately improve patient care.”

“We are exploring opportunities to collaborate with renowned, industry-leading international companies to harness and capitalize on our strength in pathology,” said Li Weimin, president of West China Hospital. “With our partners at Thermo Fisher, we are working to enhance the quality of pathological research and clinical diagnosis. We are also exploring an opportunity to extend our partnership in Western China by accelerating the development of precise pathological diagnoses that will ultimately help improve people’s lives.”

Richard Stengel, U.S. undersecretary of state for public diplomacy and public affairs, said, “In recent years, we have witnessed several achievements resulting from public and private partnerships between the U.S. and China – all of which aim to improve the well-being of people in both countries. The collaboration between Thermo Fisher and West China Hospital is a perfect example of America’s efforts to strengthen ties with China in science, technology and health. The agreement reinforces the spirit and goals of the CPE.”

The two parties have agreed to collaborate closely to make West China Hospital a leading global molecular diagnosis center. The joint efforts include construction of training bases for standardized pathology quality-control and standardized pathologic diagnosticians and the development of advanced laboratories with efficient, safe and integrated business procedures.

About West China Hospital of Sichuan University

West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH) is a prestigious medical center located on the banks of the Jinjiang River in Chengdu, the capital of Sichuan province and one of China’s most famous historical and cultural cities. WCH is one of the largest single-site hospitals in the world and a leading medical center of West China, treating complicated and severe cases, especially in the fields of living donor liver transplantation, severe acute pancreatitis, and clinical anesthesia. WCH aims to become the national center for medical scientific research and technology innovation. It has one State Laboratory, two ministry-level key laboratories, one Cooperative Research Centre online system under the Ministry of Education, and 26 open laboratories. Since 2009, the hospital has been ranked second on the China Best Hospital List on three occasions. In 2011, it was ranked 3rd in the Most Popular 3A Hospital List and 2nd in the Top 50 Chinese public general hospitals by measure of its social contribution. In 2007 and 2008, WCH won Golden Awards for hospital management from the industry body Hospital Management Asia.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005666/en/

CONTACT

Thermo Fisher Scientific Inc.
Media Contact Information:
Ron
O’Brien, 781-622-1242
ron.obrien@thermofisher.com
www.thermofisher.com
or
Investor
Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果